Xilio Therapeutics (XLO) Stock Price, News & Analysis

Company Overview

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands. These candidates are designed to selectively accumulate in tumor tissues and activate local innate and adaptive immunity. Xilio has advanced multiple assets into early‐phase clinical studies, evaluating safety, pharmacokinetics and preliminary signals of anti‐tumor activity across various solid tumor types. The pipeline also includes additional preclinical programs that apply the same targeting and activation principles to other cytokine payloads.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Xilio Therapeutics has assembled a management team with deep experience in oncology drug development and biologics engineering. The company conducts its clinical trials primarily in the United States and Europe and collaborates with academic and industry partners to accelerate the translation of its pipeline candidates into potential cancer therapies. Xilio remains committed to advancing its modular cytokine platform to address unmet needs in immuno‐oncology.

Key Stats

• Today's Range: $7.80 to $7.99
• 50-Day Range: $7.16 to $8.69
• 52-Week Range: $6.47 to $16.52
• Volume: 6,962 shs
• Average Volume: 32,971 shs
• Market Capitalization: $46.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.00
• Consensus Rating: Moderate Buy

Xilio Therapeutics Stock Analysis - MarketRank™

Xilio Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 657th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xilio Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Xilio Therapeutics has a consensus price target of $28.00, representing about 258.5% upside from its current price of $7.81.

Amount of Analyst Coverage

Xilio Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($2.39) to $0.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xilio Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xilio Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xilio Therapeutics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.31% of the float of Xilio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Xilio Therapeutics has a short interest ratio ("days to cover") of 5.92.

Change versus previous month

Short interest in Xilio Therapeutics has recently decreased by 4.48%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xilio Therapeutics does not currently pay a dividend.

Dividend Growth

Xilio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for XLO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.96% of the stock of Xilio Therapeutics is held by insiders.

Percentage Held by Institutions

54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XLO Stock Analysis - Frequently Asked Questions

How have XLO shares performed this year?

Xilio Therapeutics' stock was trading at $8.9628 at the beginning of 2026. Since then, XLO stock has decreased by 12.9% and is now trading at $7.81.

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its earnings results on Monday, March, 23rd. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.68) by $0.83. The firm had revenue of $13.69 million for the quarter, compared to the consensus estimate of $10.90 million. Xilio Therapeutics had a negative trailing twelve-month return on equity of 393.01% and a negative net margin of 80.05%.

When did Xilio Therapeutics' stock split?

Xilio Therapeutics shares reverse split on Friday, March 13th 2026.The 1-14 reverse split was announced on Thursday, March 12th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 12th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an IPO on Wednesday, October 20th 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Xilio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xilio Therapeutics investors own include PayPal (PYPL), Achilles Therapeutics (ACHL), JPMorgan Chase & Co. (JPM), AT&T (T), United Microelectronics (UMC), Adverum Biotechnologies (ADVM) and Atai Beckley (ATAI).

Company Calendar

• Last Earnings: 3/23/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XLO
• CIK: 1840233
• Web: www.xiliotx.com
• Phone: 857-524-2466
• Fax: N/A
• Employees: 70
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Xilio Therapeutics: $28.00
• High Price Target: $28.00
• Low Price Target: $28.00
• Potential Upside/Downside: +258.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.04 million
• Net Margins: -80.05%
• Pretax Margin: -80.05%
• Return on Equity: -393.01%
• Return on Assets: -33.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.58
• Quick Ratio: 2.58

Sales & Book Value

• Annual Sales: $43.77 million
• Price / Sales: 1.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.31 per share
• Price / Book: 1.07

Miscellaneous

• Outstanding Shares: 5,980,000
• Free Float: 5,447,000
• Market Cap: $46.70 million
• Optionable: Not Optionable
• Beta: -0.16